Literature DB >> 5410591

The plight of the patient with carcinoma in situ of the bladder.

D C Utz, K A Hanash, G M Farrow.   

Abstract

Entities:  

Mesh:

Year:  1970        PMID: 5410591     DOI: 10.1016/s0022-5347(17)61913-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  18 in total

Review 1.  Management of carcinoma in situ of the bladder: best practice and recent developments.

Authors:  Dominic H Tang; Sam S Chang
Journal:  Ther Adv Urol       Date:  2015-12

Review 2.  Carcinoma in situ and treatment options.

Authors:  M Erton; Y Ilker
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 3.  Bladder cancer.

Authors:  H Y Leung; T R Griffiths; D E Neal
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

4.  The current status of transurethral resection in the diagnosis and therapy of carcinoma of the urinary bladder.

Authors:  H Marberger; M Marberger; A Decristoforo
Journal:  Int Urol Nephrol       Date:  1972       Impact factor: 2.370

5.  BCG vaccine in superficial bladder cancer.

Authors:  N Sharma; S Prescott
Journal:  BMJ       Date:  1994-03-26

Review 6.  Superficial bladder cancer: state of the art.

Authors:  A V Bono
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis.

Authors:  M Takashi; S Katsuno; H Yuba; S Ohshima; K Wakai; Y Ohno
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

8.  Comparison of 30 mg and 40 mg of mitomycin C intravesical instillation in Korean superficial bladder cancer patients: prospective, randomized study.

Authors:  Chang Wook Jeong; Hwang Gyun Jeon; Cheol Kwak; Hyeon Jeong; Sang Eun Lee
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

Review 9.  Evolving immunotherapeutic strategies in bladder and renal cancer.

Authors:  T R L Griffiths; J K Mellon
Journal:  Postgrad Med J       Date:  2004-06       Impact factor: 2.401

10.  Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity in vitro.

Authors:  L Walker; M C Walker; C N Parris; J R Masters
Journal:  Urol Res       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.